XTL Biopharmaceuticals LTD income statement

In fiscal 2024, XTL Biopharmaceuticals LTD reported revenue of $451,000, operating income of −$775,000 (a -171.8% margin) and net income of −$1.0m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

XTL Biopharmaceuticals LTD: income statement, annual
Fiscal year	2024Dec 2024
Revenue	451
Cost of revenue	448
Gross profit	3
Research and development	16
Operating income	−775
Interest expense	28
Income before tax	240
Income tax	−130
Net income	−1,027
Diluted shares (average)	7m
EBITDA	−576

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from XTL Biopharmaceuticals LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to XTL Biopharmaceuticals LTD.